Response Pharmaceuticals is developing its lead asset, RDX-002, a first-in-class weight management and cardiometabolic health drug with confirmed efficacy and safety in >550 subjects. All programs are in Phase 2 clinical development.
Our initial focus is on helping underserved patient populations taking antipsychotic medications for disabling mental illnesses to combat weight gain and metabolic dysregulation associated with these treatments. Antipsychotic-induced weight gain (AIWG) is a drug-induced epidemic within the already vulnerable population of patients with severe mental illness, and is contributing to a growing mortality gap between people with mental illness and the general population.
Additionally, RDX-002 is being evaluated in other settings in which clinically significant weight gain and/or adverse metabolic changes are prevalent.
Company Details
- Employees
- 10
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Response Pharmaceuticals Questions
Response Pharmaceuticals's website is http://www.responsepharmaceuticals.com
Response Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/response-pharmaceuticals
Response Pharmaceuticals has
10 employees.
View email and phone details for 10
employees at Response Pharmaceuticals.
Response Pharmaceuticals's industry is
Biotechnology Research
Response Pharmaceuticals's top competitors are
Retension Pharmaceuticals,
Volastra Therapeutics,
Noveome Biotherapeutics, Inc.,
Monod Bio,
Cinrx Pharma,
Applied Therapeutics, Inc.,
Voyager Therapeutics, Inc.,
Rivus Pharmaceuticals,
Endevica Bio,
Empros Pharma.
Response Pharmaceuticals's categories are Biotechnology Research
Response Pharmaceuticals's founding year is 2022
